Physician profile
David H Lee
NPI 1003848714
$8,813.05
in general payments reported to CMS, 2019-2025
23 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $711 · 2021: $968 · 2022: $1,333 · 2023: $994 · 2024: $1,568 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,523.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $1,138.21 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $1,085.24 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $855.12 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $834.55 | 2019-2021 | |
| Allergan, INC. | $747.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $724.09 | 2019-2023 | |
| Abbvie INC. | $689.46 | 2022-2025 | |
| Alcon Vision LLC | $558.66 | 2022-2025 | Simbrinza, Rocklatan, Rhopressa |
| Tarsus Pharmaceuticals, INC. | $482.38 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $381.15 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $360.18 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $263.09 | 2019-2021 | |
| Shire North American Group INC | $172.48 | 2019 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Thea Pharma INC. | $96.26 | 2024-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $93.67 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $83.01 | 2020-2024 | Tecnis Simplicity |
| Astellas Pharma US INC | $25.69 | 2023 | Izervay |
| Dompe US, INC. | $22.05 | 2025 | Oxervate |
| Sight Sciences, INC. | $20.99 | 2020 | |
| Mallinckrodt Enterprises LLC | $19.85 | 2019 | |
| Horizon Therapeutics Plc | $19.05 | 2023 | Tepezza |
| Novo Nordisk INC | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.